We developed a diagnostic prediction model (age >65, BMP3, RASSF1A, BNC1, MESTv2, TFPI2, APC, SFRP1 and SFRP2), which was able to differentiate between pancreatic adenocarcinoma and a large control group of great clinical relevance. This evidence concerns the gene SFRP2 and pancreatic adenocarcinoma.